PR95117

MILAN, March 22, 2022, /PRNewswire=KYODO JBN/ --

M-Squared Consulting, a consultancy company for life sciences companies in the

management of pharmaceutical contracts, has received a first positive signal

from EMA's Pandemic Task Force in the Rapid Scientific Advice1 procedure for

potential treatments for Covid-19 in the repositioning project for

cyclobenzaprine, a drug for the treatment of acute musculoskeletal conditions.

Cyclobenzaprine, based on preclinical scientific evidence, has been shown to

inhibit viral replication by interfering in at least two steps of the infection

process - entry and replication - and to represent a novel therapeutic solution

for the treatment of Covid-19.

The mechanism of action intervenes in the infection process and the molecule

has the ability to reach the central nervous system, allowing the development

of an effective therapy for Neuro-Covid symptoms, whose efficacy against

variants will have to be verified.

“EMA's support is a milestone for the project, a milestone that marks a

fundamental starting point" says Manuel Bellasi, CEO of m-Squared -. We will

now continue with the research and development of what could be one of the most

promising treatments for Covid-19”.

References:

1. COVID-19 treatments that have received EMA advice

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development#covid-19-treatments-that-have-received-ema-advice-section

agenziafarmaco.gov.it)

Logo - https://mma.prnewswire.com/media/1771401/m_Squared_Consulting.jpg

Source: m-Squared Consulting S.r.L